The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions

International Journal of Clinical Practice

Volumn 68, Issue 4, 2014, Pages 465-470

  Adler, G ^a   Mueller, B ^b   Articus, K ^b  

^a Institut für Studien Zur Psychischen Gesundheit ISPG   (Germany)

^b Novartis Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE; NEUROPROTECTIVE AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER BURDEN; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; CONFUSION; CONTACT DERMATITIS; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MORISKY QUESTIONNAIRE; MULTICENTER STUDY; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; QUESTIONNAIRE; RESTLESSNESS; SKIN ALLERGY; SKIN MANIFESTATION; CAREGIVER; CLINICAL TRIAL; COST OF ILLNESS; MEDICATION COMPLIANCE; STATISTICS AND NUMERICAL DATA; TRANSDERMAL PATCH;

AGED; ALZHEIMER DISEASE; CAREGIVERS; COST OF ILLNESS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES; RIVASTIGMINE; SURVEYS AND QUESTIONNAIRES; TRANSDERMAL PATCH;

EID: 84897383032     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12374     Document Type: Article

References (13)

1. Di Stefano A, Iannitelli A, Laserra S, Sozio P,. Drug delivery strategies for Alzheimer's disease treatment. Expert Opin Drug Deliv 2011; 8: 581-603.
2. Grossberg G, Meng X, Olin JT,. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2011; 26: 65-71.
3. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-67.
4. Cummings J, Froelich L, Black SE, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm) in Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 33: 341-53.
5. Dhillon S,. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. Drugs 2011; 71: 1209-31.
6. Dhillon S,. Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type. Drugs Aging 2011; 28: 927-30.
7. Blesa Gonzalez R, Boada Rovira M, Martinez Parra C, et al. Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease. Neurologia 2011; 26: 262-71.
8. Molinuevo JL, Arranz FJ,. Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease. Expert Rev Neurother 2012; 12: 31-7.
9. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 485-91.
10. Morisky DE, Green LW, Levine DM,. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
11. Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69: S14-22.
12. Seibert J, Tracik F, Articus K, Spittler S,. Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice. Neuropsychiatr Dis Treat 2012; 8: 141-7.
13. Articus K, Baier M, Tracik F, et al. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. Int J Clin Pract 2011; 65: 790-6.